Protocol Ledger

NCT04745351 · Phase III · TERMINATED

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

Interventional Phase III clinical trial protocol NCT04745351 sponsored by Gilead Sciences in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-31 Enrollment: 249 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04745351
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)249 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04745351
Protocol FieldVerified Registry Value
NCT IdentifierNCT04745351
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment249 participants (ACTUAL)
Registered Start Date2021-03-31
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04745351
Hospital Research SiteLocationSite Profile
Hoag Memorial Hospital PresbyterianNewport Beach, CAOpen Hospital Dossier ->
Sutter Medical Center SacramentoSacramento, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI